Perth Researchers Discover Garlic as Possible Migraine Solution

Researchers at the University of Western Australia’s School of Medicine and Pharmacology have initiated a clinical trial exploring the potential of garlic as a natural remedy for migraine headaches, according to a report from The West Australian. The study, led by Dr. Emily Tan, a neurologist specializing in headache disorders, aims to evaluate whether allicin—a compound found in garlic—can reduce migraine frequency or severity.

The trial, which began in June 2026, involves 120 participants aged 18 to 65 who experience episodic migraines. Participants are divided into two groups: one receiving a standardized garlic extract supplement containing 10 mg of allicin daily, and the other receiving a placebo. Researchers will monitor changes in migraine frequency, duration, and intensity over a 12-week period, with follow-up assessments conducted at three and six months post-trial.

Dr. Tan noted that preliminary evidence suggests garlic may have anti-inflammatory and vasodilatory properties that could alleviate migraine symptoms. “Migraines are complex neurological conditions often linked to vascular changes and inflammation,” she said. “While conventional treatments like triptans and beta-blockers are effective for many, some patients seek alternatives due to side effects or limited efficacy.”

The study builds on anecdotal reports and small-scale studies suggesting garlic’s potential. A 2017 pilot study published in *Phytotherapy Research* found that participants taking garlic supplements experienced a 20% reduction in migraine days compared to a control group. However, the sample size of 30 was limited, and the study lacked a double-blind design. The current trial aims to address these limitations with a larger, more rigorous methodology.

Garlic’s active compound, allicin, is known for its antimicrobial and antioxidant properties. Previous research has also linked garlic to improved cardiovascular health, though its mechanisms for migraine relief remain unclear. Dr. Tan emphasized that the trial will investigate both physiological and subjective outcomes. “We’ll measure biomarkers of inflammation and vascular activity, as well as patient-reported symptom changes,” she said.

The University of Western Australia’s trial is funded by the Australian National Health and Medical Research Council (NHMRC) and supported by the Western Australian Department of Health. Researchers have partnered with a local pharmaceutical company to supply the garlic extract, which is produced using a cold-press method to preserve allicin content.

Public health experts have cautiously welcomed the initiative. Dr. Mark Harris, a professor of neurology at the University of Sydney not involved in the study, stated, “Natural remedies can play a role in migraine management, but they must be rigorously tested. This trial is a step forward, though results won’t be known for months.” He noted that migraines affect approximately 1 in 7 Australians, with significant economic and social impacts.

Participants in the trial are required to maintain diaries tracking migraine episodes, medication use, and lifestyle factors. Blood samples will be collected at baseline, six weeks, and 12 weeks to analyze inflammatory markers such as C-reactive protein (CRP) and interleukin-6 (IL-6). The study’s primary endpoint is the reduction in migraine days, while secondary outcomes include improvements in sleep quality and mood, which are often disrupted by chronic migraines.

The trial’s findings could influence future treatment guidelines if garlic demonstrates consistent efficacy. However, researchers caution against self-medication with garlic supplements, as high doses may interact with anticoagulant medications or cause gastrointestinal side effects. “This is a scientific investigation, not a recommendation for public use,” Dr. Tan clarified. “We need to establish safety and effectiveness before considering broader applications.”

Results from the trial are expected in late 2027. If preliminary data shows promise, larger Phase III studies may follow. The research team has also plans to explore garlic’s potential for other headache types, such as tension-type headaches, which are more common but less studied than migraines.

Meanwhile, the Australian Migraine Foundation has urged patients to consult healthcare providers before trying alternative therapies. “While this study is promising, it’s important to remember that migraines require personalized care,” said spokesperson Sarah Mitchell. “Patients should not discontinue prescribed treatments without medical advice.”

The University of Western Australia’s trial aligns with global efforts to integrate complementary medicine into evidence-based practices. Similar studies are underway in the United Kingdom and Germany, though none have yet produced conclusive results. The Perth researchers emphasize that their work is part of a broader movement to explore natural products for chronic conditions, provided they meet scientific standards.